Is ESTA or GKOS more profitable?

Establishment Labs has a net margin of -19.05% compared to Glaukos' net margin of -30.68%. Glaukos' return on equity of -6.37% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -19.05% -218.77% -12.31% Glaukos -30.68% -6.37% -4.78%

Does the media refer more to ESTA or GKOS?

In the previous week, Glaukos had 24 more articles in the media than Establishment Labs. MarketBeat recorded 30 mentions for Glaukos and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.33 beat Glaukos' score of 0.66 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Glaukos 10 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, ESTA or LQDA?

Establishment Labs has higher revenue and earnings than Liquidia. Establishment Labs is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $211.08M 12.90 -$51.06M -$1.49 N/A Liquidia $158.32M 47.25 -$68.92M $0.14 600.79

Does the media refer more to ESTA or LQDA?

In the previous week, Liquidia had 15 more articles in the media than Establishment Labs. MarketBeat recorded 21 mentions for Liquidia and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.33 beat Liquidia's score of 0.69 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ESTA or STVN?

Establishment Labs presently has a consensus price target of $90.43, suggesting a potential downside of 2.28%. Given Establishment Labs' higher possible upside, equities research analysts clearly believe Establishment Labs is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Establishment Labs 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media favor ESTA or STVN?

In the previous week, Establishment Labs had 5 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for Establishment Labs and 1 mentions for Stevanato Group. Establishment Labs' average media sentiment score of 1.33 beat Stevanato Group's score of 1.08 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ESTA or BLCO?

In the previous week, Bausch + Lomb had 10 more articles in the media than Establishment Labs. MarketBeat recorded 16 mentions for Bausch + Lomb and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.33 beat Bausch + Lomb's score of 0.31 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bausch + Lomb 3 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ESTA or MMED?

In the previous week, MiniMed Group had 3 more articles in the media than Establishment Labs. MarketBeat recorded 9 mentions for MiniMed Group and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.33 beat MiniMed Group's score of 0.40 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 0 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Establishment Labs (ESTA) Competitors

$92.54 -0.94 (-1.01%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$92.59 +0.05 (+0.05%)

As of 07/31/2026 07:34 PM Eastern

Compare

ESTA vs. GKOS, LQDA, STVN, BLCO, and MMED

Should you buy Establishment Labs stock or one of its competitors? MarketBeat compares Establishment Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Establishment Labs include Glaukos (GKOS), Liquidia (LQDA), Stevanato Group (STVN), Bausch + Lomb (BLCO), and MiniMed Group (MMED).

How does Establishment Labs compare to Glaukos?

Establishment Labs (NASDAQ:ESTA) and Glaukos (NYSE:GKOS) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Establishment Labs has a net margin of -19.05% compared to Glaukos' net margin of -30.68%. Glaukos' return on equity of -6.37% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Glaukos	-30.68%	-6.37%	-4.78%

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 5.9% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Establishment Labs has higher earnings, but lower revenue than Glaukos. Establishment Labs is trading at a lower price-to-earnings ratio than Glaukos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.90	-$51.06M	-$1.49	N/A
Glaukos	$612.84M	15.96	-$187.69M	-$3.25	N/A

In the previous week, Glaukos had 24 more articles in the media than Establishment Labs. MarketBeat recorded 30 mentions for Glaukos and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.33 beat Glaukos' score of 0.66 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	10 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs currently has a consensus target price of $90.43, suggesting a potential downside of 2.28%. Glaukos has a consensus target price of $177.33, suggesting a potential upside of 6.49%. Given Glaukos' stronger consensus rating and higher probable upside, analysts clearly believe Glaukos is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

Establishment Labs has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Glaukos has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Summary

Glaukos beats Establishment Labs on 10 of the 16 factors compared between the two stocks.

How does Establishment Labs compare to Liquidia?

Establishment Labs (NASDAQ:ESTA) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Establishment Labs presently has a consensus price target of $90.43, indicating a potential downside of 2.28%. Liquidia has a consensus price target of $86.18, indicating a potential upside of 2.46%. Given Liquidia's stronger consensus rating and higher possible upside, analysts clearly believe Liquidia is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

Establishment Labs has higher revenue and earnings than Liquidia. Establishment Labs is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.90	-$51.06M	-$1.49	N/A
Liquidia	$158.32M	47.25	-$68.92M	$0.14	600.79

In the previous week, Liquidia had 15 more articles in the media than Establishment Labs. MarketBeat recorded 21 mentions for Liquidia and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.33 beat Liquidia's score of 0.69 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Liquidia has a net margin of 7.74% compared to Establishment Labs' net margin of -19.05%. Liquidia's return on equity of 46.82% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Liquidia	7.74%	46.82%	7.06%

Establishment Labs has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Summary

Liquidia beats Establishment Labs on 11 of the 17 factors compared between the two stocks.

How does Establishment Labs compare to Stevanato Group?

Establishment Labs (NASDAQ:ESTA) and Stevanato Group (NYSE:STVN) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Establishment Labs had 5 more articles in the media than Stevanato Group. MarketBeat recorded 6 mentions for Establishment Labs and 1 mentions for Stevanato Group. Establishment Labs' average media sentiment score of 1.33 beat Stevanato Group's score of 1.08 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.9% of Establishment Labs shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 0.7% of Stevanato Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Establishment Labs presently has a consensus price target of $90.43, suggesting a potential downside of 2.28%. Given Establishment Labs' higher possible upside, equities research analysts clearly believe Establishment Labs is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Stevanato Group has a net margin of 11.76% compared to Establishment Labs' net margin of -19.05%. Stevanato Group's return on equity of 10.27% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Stevanato Group	11.76%	10.27%	6.08%

Establishment Labs has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Stevanato Group has higher revenue and earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.90	-$51.06M	-$1.49	N/A
Stevanato Group	€1.34B	4.49	€158.21M	€0.59	33.71

Summary

Stevanato Group beats Establishment Labs on 9 of the 17 factors compared between the two stocks.

How does Establishment Labs compare to Bausch + Lomb?

Establishment Labs (NASDAQ:ESTA) and Bausch + Lomb (NYSE:BLCO) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Establishment Labs currently has a consensus target price of $90.43, suggesting a potential downside of 2.28%. Bausch + Lomb has a consensus target price of $18.67, suggesting a potential upside of 10.50%. Given Bausch + Lomb's higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Bausch + Lomb had 10 more articles in the media than Establishment Labs. MarketBeat recorded 16 mentions for Bausch + Lomb and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.33 beat Bausch + Lomb's score of 0.31 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	3 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Establishment Labs has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Bausch + Lomb has a net margin of -3.21% compared to Establishment Labs' net margin of -19.05%. Bausch + Lomb's return on equity of 4.14% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Bausch + Lomb	-3.21%	4.14%	1.93%

Establishment Labs has higher earnings, but lower revenue than Bausch + Lomb. Establishment Labs is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.90	-$51.06M	-$1.49	N/A
Bausch + Lomb	$5.10B	1.18	-$360M	-$0.48	N/A

Summary

Establishment Labs and Bausch + Lomb tied by winning 8 of the 16 factors compared between the two stocks.

How does Establishment Labs compare to MiniMed Group?

Establishment Labs (NASDAQ:ESTA) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Comparatively, 2.2% of MiniMed Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, MiniMed Group had 3 more articles in the media than Establishment Labs. MarketBeat recorded 9 mentions for MiniMed Group and 6 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.33 beat MiniMed Group's score of 0.40 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiniMed Group has a net margin of 0.00% compared to Establishment Labs' net margin of -19.05%. MiniMed Group's return on equity of 0.00% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
MiniMed Group	N/A	N/A	N/A

Establishment Labs has higher earnings, but lower revenue than MiniMed Group. Establishment Labs is trading at a lower price-to-earnings ratio than MiniMed Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.90	-$51.06M	-$1.49	N/A
MiniMed Group	$3.10B	1.63	-$190.97M	-$0.68	N/A

Establishment Labs currently has a consensus price target of $90.43, suggesting a potential downside of 2.28%. MiniMed Group has a consensus price target of $21.62, suggesting a potential upside of 19.75%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts plainly believe MiniMed Group is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

MiniMed Group beats Establishment Labs on 10 of the 15 factors compared between the two stocks.

Get Establishment Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESTA vs. The Competition

Export

Metric	Establishment Labs	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.75B	$5.68B	$7.23B	$12.30B
Dividend Yield	N/A	1.78%	2.59%	9.45%
P/E Ratio	-62.11	23.00	281.76	24.66
Price / Sales	12.90	57.02	641.27	110.52
Price / Cash	N/A	32.26	71.02	59.62
Price / Book	114.25	6.31	11.09	5.90
Net Income	-$51.06M	$148.76M	$3.50B	$336.31M
7 Day Performance	0.24%	1.77%	-0.28%	0.09%
1 Month Performance	3.71%	5.34%	-3.01%	-5.67%
1 Year Performance	123.85%	2.08%	61.94%	18.79%

Establishment Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESTA Establishment Labs	2.0259 of 5 stars	$92.54 -1.0%	$90.43 -2.3%	+120.5%	$2.75B	$211.08M	N/A	1,004	News Coverage Positive News Upcoming Earnings
GKOS Glaukos	1.9552 of 5 stars	$149.69 -1.5%	$155.23 +3.7%	+93.5%	$8.72B	$507.44M	N/A	1,094	Trending News Earnings Report Analyst Forecast Insider Trade
LQDA Liquidia	3.0557 of 5 stars	$84.61 +0.2%	$86.18 +1.9%	+350.0%	$7.48B	$288.07M	600.46	50	Insider Trade
STVN Stevanato Group	3.032 of 5 stars	€19.86 +0.3%	N/A	-19.4%	€6.01B	€1.34B	33.66	6,010	Positive News
BLCO Bausch + Lomb	3.1802 of 5 stars	$16.45 +1.1%	$18.23 +10.8%	+23.5%	$5.87B	$5.21B	N/A	13,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESTA) was last updated on 8/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Establishment Labs (ESTA) Competitors

ESTA vs. GKOS, LQDA, STVN, BLCO, and MMED

How does Establishment Labs compare to Glaukos?

Summary

How does Establishment Labs compare to Liquidia?

Summary

How does Establishment Labs compare to Stevanato Group?

Summary

How does Establishment Labs compare to Bausch + Lomb?

Summary

How does Establishment Labs compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESTA vs. The Competition

Establishment Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Establishment Labs (ESTA) Competitors

ESTA vs. GKOS, LQDA, STVN, BLCO, and MMED

How does Establishment Labs compare to Glaukos?

Is ESTA or GKOS more profitable?

Do institutionals and insiders hold more shares of ESTA or GKOS?

Which has preferable valuation and earnings, ESTA or GKOS?

Does the media refer more to ESTA or GKOS?

Do analysts recommend ESTA or GKOS?

Which has more volatility & risk, ESTA or GKOS?

Summary

How does Establishment Labs compare to Liquidia?

Do analysts recommend ESTA or LQDA?

Which has stronger earnings & valuation, ESTA or LQDA?

Does the media refer more to ESTA or LQDA?

Do institutionals & insiders hold more shares of ESTA or LQDA?

Is ESTA or LQDA more profitable?

Which has more volatility and risk, ESTA or LQDA?

Summary

How does Establishment Labs compare to Stevanato Group?

Does the media favor ESTA or STVN?

Do institutionals and insiders hold more shares of ESTA or STVN?

Do analysts rate ESTA or STVN?

Is ESTA or STVN more profitable?

Which has more risk and volatility, ESTA or STVN?

Which has stronger earnings and valuation, ESTA or STVN?

Summary

How does Establishment Labs compare to Bausch + Lomb?

Do insiders and institutionals have more ownership in ESTA or BLCO?

Do analysts prefer ESTA or BLCO?

Does the media favor ESTA or BLCO?

Which has more risk and volatility, ESTA or BLCO?

Is ESTA or BLCO more profitable?

Which has better valuation & earnings, ESTA or BLCO?

Summary

How does Establishment Labs compare to MiniMed Group?

Do insiders & institutionals have more ownership in ESTA or MMED?

Does the media refer more to ESTA or MMED?

Is ESTA or MMED more profitable?

Which has better earnings & valuation, ESTA or MMED?

Do analysts rate ESTA or MMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESTA vs. The Competition

Establishment Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools